About this item:

670 Views | 0 Downloads

Author Notes:

Corresponding author: Phone: 404-712-8680; Fax: 404-727-6689; asun2@emory.edu


Research Funding:

This work was supported, in part, by Public Health Service Grants AI071002 and AI085328 (to R. K. P.) from the NIH/NIAID and by Public Health Service Grant HG003918-02 (to J.P.S.) from the NIH.


  • Host-directed
  • non-nucleoside
  • small molecule inhibitor
  • influenza virus
  • myxovirus
  • benzimidazole

Host-directed Inhibitors of Myxoviruses: Synthesis and in vitro Biochemical Evaluation


Journal Title:

ACS Medicinal Chemistry Letters


Volume 2, Number 11


, Pages 798-803

Type of Work:

Article | Post-print: After Peer Review


Drugs targeted to viral proteins are highly vulnerable to the development of viral resistance. One little explored approach to the treatment of viral diseases is the development of agents that target host factors required for virus replication. Myxoviruses are predominantly associated with acute disease and, thus, ideally suited for this approach since the necessary treatment time is anticipated to be limited. High-throughput screening previously identified benzimidazole 22407448 with broad anti-viral activity against different influenza virus and paramyxovirus strains. Hit to lead chemistry has generated 6p (JMN3-003) with potent antiviral activity against a panel of myxovirus family members exhibiting EC50 values in the low nanomolar range.

Copyright information:

© 2011 American Chemical Society

Export to EndNote